Behavioral responses are altered in piglets with decreased frontal cortex docosahexaenoic acid.
Docosahexaenoic acid [22:6(n-3)] is required in large amounts for membrane lipid synthesis during brain growth. The functional importance of differences in dietary fatty acid intakes that alter brain 22:6(n-3), however, is not well understood. We used a dietary approach to manipulate 22:6(n-3) in piglet brain and assessed the effects on behavior and change in behavior on an elevated plus maze after administration of L-dihydroxyphenylalanine (L-Dopa) or sulperide, a dopamine D2 receptor blocker. Piglets were fed 1.2% energy 18:2(n-6) and 0.05% energy 18:3(n-3) (low PUFA), or 10.7% energy 18:2(n-6), 1.1% energy 18:3(n-3), 0.3% energy 20:4(n-6) and 0.3% energy 22:6(n-3) (high PUFA) from 1 d of age and behavior assessed at 18-22 d of age. At 30 d of age, frontal cortex dopamine, and phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidyethanolamine (PE) and phosphatidylinositol (PI) fatty acids were quantified. Piglets fed the low PUFA diet had fewer arm entries on the maze than piglets fed the high PUFA diet, P = 0.02. L-Dopa increased the open (P = 0.005) and closed (P = 0.04) arm entries by piglets fed the low PUFA diet. Behavior did not differ between piglets fed the low and high PUFA diets when given L-Dopa. Frontal cortex PC, PS and PE 22:6(n-3) was lower and 22:5(n-6) was higher in piglets fed the low compared with the high PUFA diet, P < 0.01. Our work establishes the neonatal piglet as a model with which to study the behavioral effects of diet-induced changes in brain 22:6(n-3), and provides functional evidence that brain 22:6(n-3) is important in central dopamine metabolism.
Ng
Kai-Fong
KF
Department of Paediatrics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4.
Innis
Sheila M
SM
D000375:Aging; D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000502:physiology*; D001921:Brain / Q000254:growth & development; D004032:Diet; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D004298:Dopamine / Q000032:analysis; D065127:Dopamine D2 Receptor Antagonists; D002149:Energy Intake; D005227:Fatty Acids / Q000032:analysis; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D005625:Frontal Lobe / Q000737:chemistry*; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D009929:Organ Size; D010713:Phosphatidylcholines / Q000032:analysis; D010714:Phosphatidylethanolamines / Q000032:analysis; D010716:Phosphatidylinositols / Q000032:analysis; D010718:Phosphatidylserines / Q000032:analysis; D013469:Sulpiride / Q000008:administration & dosage; D013552:Swine; D015430:Weight Gain
D004042:Dietary Fats, Unsaturated; D065127:Dopamine D2 Receptor Antagonists; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D010718:Phosphatidylserines; D004281:Docosahexaenoic Acids; D007980:Levodopa; D013469:Sulpiride; D004298:Dopamine